Can an immune booster make CAR-T therapy last longer in myeloma?
NCT ID NCT07200089
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests whether adding a drug called NT-I7 (a lab-made immune booster) can help CAR-T cells survive longer in people with multiple myeloma that has come back or stopped responding to treatment. About 52 participants who are already getting standard CAR-T therapy will receive either NT-I7 or a placebo. The main goal is to check safety and find the best dose, while also seeing if the drug improves the cancer-fighting power of CAR-T cells.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NT-I7 (recombinant human IL-7, also called Efineptakin alfa)
What this could lead to
If it works, this could help CAR-T cells last longer in the body, potentially improving control of multiple myeloma and delaying relapse.
What could go wrong
This is a very early Phase 1 trial with only 52 people, so it's too soon to know if it works. The drug may cause side effects or fail to improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact